TREVENTIS™ Corporation is a biotechnology company focused on diseases associated with protein misfolding. Treventis uses a computational platform to rationally design small molecule therapeutics for protein misfolding diseases. Our lead program in Alzheimer’s Disease therapeutics is now the subject of a robust collaboration with Servier Laboratories. We have a team of chemists and biologists with leading expertise in this area and are expanding on our proprietary pipeline in Parkinson’s, ALS, an undisclosed oncology target and in rare diseases. We also have a diagnostics division for the early identification of Alzheimer’s disease.
Chief Executive Officer
Dr. Barden, a registered patent agent and computational scientist, has over ten years of experience in drug discovery management. A veteran of programs in the neurodegenerative and anti-infective spaces, he developed the Company’s virtual high-throughput screening library (>11 million compounds) and is a key architect of our proprietary “CCM” model of protein misfolding. Dr. Barden received his Ph.D. in Physical Chemistry from the University of Georgia.
Chief Medical Officer
Dr. Weaver is Director of the Krembil Research Institute and Professor in the Departments of Medicine, Chemistry and Pharmacy at the University of Toronto. He has published over 150 peer-reviewed articles and is an inventor on over 70 patents. In addition to being a practicing neurologist Dr. Weaver is a recognized expert in computer-aided drug design. Dr. Weaver’s work in the fields of quantum and molecular mechanics to design drugs through the use of high throughput in-silico screens has been instrumental in his founding of several biotech companies. Most notably at Neurochem Inc. Dr. Weaver discovered and developed tramiprosate (Alzhemed), the first “disease modifying” small molecule anti-amyloid aggregation drug in the world to reach phase 3 clinical trials for the treatment of Alzheimer’s Disease. Following an IPO, Neurochem was publicly traded on the Toronto Stock Exchange and NASDAQ. Dr. Weaver is the recipient of numerous grants, awards and honors a selection of which include the 2011 Jonas Salk Award, 2010 Bantrel Award, 2009 Prix Galien (for research into the cause of Alzheimer’s Disease) and the 2003 Queen Elizabeth II Jubilee Medal. Dr. Weaver is the past President of Epilepsy Canada. He received his M.D. and Ph.D. degrees from Queen’s University in Kingston, Ontario, Canada.
Chief Scientific Officer
Dr. Reed is a founder of Treventis and co-inventor of our lead and backup series of small molecule inhibitors of tau and abeta oligomerization. Dr. Reed was instrumental in leading the company’s pharmacology and chemistry efforts to obtain in vivo dose response reduction and target engagement of tau and abeta oligomers in models of neurodegeneration, culminating in a partnership with the pharmaceutical group Servier. Prior to Treventis, Dr. Reed held several senior scientist positions in medicinal chemistry at ICOS Corporation and Schering Plough Research Institute, where he focused in the areas of oncology, anti-infectives and inflammation. Dr. Reed has published multiple patents and publications in the field of neurodegeneration, participated on the Alzheimer’s Association of Canada grant review panel, and held a two-term appointment as assistant Professor of medicinal chemistry at Dalhousie University. He received a B.Sc in chemistry from the University of Reading and D.Phil in organic chemistry from the University of Sussex.
Dr. Taylor heads up a team of researchers working to develop screening tools for amyloid drug discovery, including proof of concept and mechanism of action studies. A variety of biophysical, biochemical, cell-based, and in vivo tests are being developed in house and in collaboration with other scientists worldwide. Prior to joining Treventis, Dr. Taylor led the biology program at DeNovaMed, a Halifax, Nova Scotia based company developing novel anti-infectives. Dr. Taylor was awarded her PhD in Biochemistry and Molecular Biology from Dalhousie University, Canada, followed by postdoctoral training in Biochemistry at the University of Geneva, Switzerland.
Biology Group Leader
Dr. Yang is a Principal Scientist at Treventis Corporation, leading the Biological Sciences Group of the company. Dr. Yang has over ten years of experience in the research of protein misfolding in the neurodegenerative diseases such as Alzheimer’s disease and ALS. He joined Treventis Corporation in 2013 and played a key role in developing bioassays for Abeta and tau program of the company. He received his Ph.D. in Molecular and Cellular Biology with study of the interaction between Alzheimer’s beta-amyloid peptide and VEGF from Pohang University of Science and Technology (POSTECH); and did his postdoctoral training in Dr. Peter St. George-Hyslop’s lab in the University of Toronto.
Chemistry Group Leader
Dr. Wu, a medicinal and synthetic organic chemist, has over ten years of experience in drug discovery. Besides his experience in Alzheimer’s disease, he developed a new class of antibacterial compounds now in preclinical testing and is a veteran of other CNS and oncology campaigns. Dr. Wu received his Ph.D. in Applied Chemistry from SINOPEC Research Institute of Petroleum Processing.